GlassScriptPhysician profile
Rizwan H Khan
NPI 1700864881
$3,444.22
in general payments reported to CMS, 2019-2025
26 companies · $936 in 2025
The $936 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $282 · 2021: $194 · 2022: $180 · 2023: $173 · 2024: $395 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454 · Education: $34.00 · Consulting Fee: $15.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.95 |
| Education | $34.00 |
| Consulting Fee | $15.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.94 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $729.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $373.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.15 | 2019-2025 | Dupixent |
| Csl Behring | $201.59 | 2019-2025 | Haegarda |
| Pfizer INC. | $194.34 | 2019-2025 | |
| Amgen INC. | $158.53 | 2022-2025 | Tezspire |
| Genzyme Corporation | $136.31 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $110.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.47 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $59.07 | 2020-2021 | |
| Jubilant Hollisterstier LLC | $51.39 | 2021 | |
| Greer Laboratories, INC. | $35.34 | 2019-2025 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $32.38 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $32.16 | 2025 | Dawnzera |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.12 | 2025 | Xolair |
| Shire North American Group INC | $30.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.96 | 2025 | Takhzyro |
| Biocryst US Sales Co., LLC | $22.22 | 2023 | Orladeyo |
| Grifols USA, LLC | $21.73 | 2019 | |
| Merck Sharp & Dohme LLC | $18.52 | 2023 | |
| Pharming Healthcare, INC. | $18.00 | 2019 | |
| Optinose US, INC. | $15.82 | 2019 | |
| Adma Biomanufacturing LLC | $15.71 | 2025 | |
| Alk-Abello, INC | $11.79 | 2019 | |
| Kaleo, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.